Panacea Biotec Limited has informed the Exchange regarding a press release dated Jun 08, 2026, titled "Launch of the DENSTAR project: advancing the licensure of a tetravalent liveattenuateddengue vaccine (DengiAll®) in sub-Saharan Africa and to facilitate its global access".
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Panacea Biotec has announced the launch of the DENSTAR project, aimed at pushing forward the regulatory licensure of its tetravalent live-attenuated dengue vaccine, DengiAll®, in sub-Saharan Africa and supporting its global access. This is a development-stage initiative focused on advancing a key product pipeline asset rather than a commercial order or approval event. The press release is dated June 8, 2026. No specific revenue figures, order values, or financial guidance were disclosed in the filing.
Positive sentiment for long-term pipeline visibility and potential future revenues from Africa, but no immediate impact on financials or near-term stock price is implied, as no approval, order, or guidance change has occurred.